Levine Keszler has an established practice for clients in the biotechnology, pharmaceutical and life science industries. We mostly represent biotechnology companies in the development stage, as well as private equity and venture capital investors. We have direct experience dealing with the business development functions of our client. We draft agreements with key suppliers and subcontractors (CMOs and CROs), licensing-in and licensing-out agreements and advise our life-sciences client in the equity offerings.
Levine Keszler also regularly advises investment funds in the context of transactions in the healthcare sector, and biotechnology, pharmaceutical and life science companies for their M&A transactions.
Advising RAD-x, a pan-European buy and build platform specialized in medical imaging, in connection with its second round of equity financing by a major Private Equity fund (2018).
Advising Maincare Solutions, a medical software editor, on its acquisition of Savart & Michel, a hospital logistics software editor (2017).
Assisting a network of pharmacies in the context of the acquisition of several groups of pharmacies (2018 -2017).
Assisting a group of investors in the setting-up of a Swiss-based group procurement organization network (2016).
Advising a group of investors in connection with the creation of MenaLabs, a network of medical laboratories in the Middle East and Northern Africa Region (financing and joint venture with Cerba Healthcare, a leading European diagnostic company) (2016).
Advising RAD-x for its creation and equity financing by Gilde Healthcare and Advising its founders in connection with their management package (2016).
Assisting the founders of a major French biotech company in their sale process (2015).
Assisting a French specialty pharmaceutical company in the negotiation of a number of contracts with key suppliers and subcontractors (CROs and CMOs) (2017 – 2012), in connection with 13 ongoing phase III trials.